While companies in the opiod sector have had to deal with headlines about abuse as well as pharma pricing controversies, Depomed reported increased sales across its product line. Depomed , a pharmaceutical company focused on developing products to treat pain and best known for its drug NUCYNTA, finished 2016 with full-year, non-GAAP adjusted earnings of $1.15 per share.